| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC47915 | RET-IN-7 | RET-IN-7 demonstrates potent in vitro RET kinase inhibition and robust in vivo efficacy in RET-driven tumor xenografts upon multiday dosing in mice. |
|
| DC47979 | HNMPA | HNMPA is a membrane impermeable insulin receptor tyrosine kinase inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities |
|
| DC48025 | Cevidoplenib dimesylate Featured | Cevidoplenib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities. |
|
| DC48033 | BTK-IN-5 | BTK-IN-5 is a covalent BTK inhibitor for treating medical conditions such as cardiovascular diseases, respiratory diseases, inflammation, and diabetes. |
|
| DC48043 | BIIB091 Featured | BIIB091 is a novel reversible, selective, potent BTK inhibitor with Kd of 0.07 nM. |
|
| DC48357 | BCPyr | BCPyr is a new candidate BTK degrader (DC50 = 800 nM). |
|
| DC48358 | BMS-986143 | BMS-986143 is an orally active, reversible BTK inhibitor with an IC50 of 0.26 nM. BMS-986143 also inhibits TEC, BLK, BMX, TXK FGR, YES1, ITK with IC50s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM,19 nM, 21 nM, respectively. BMS-986143 can be used for the research of autoimmune diseases. |
|
| DC48359 | Bezuclastinib Featured | Bezuclastinib (PLX 9486; CGT9486) is a potent inhibitor of c-kit and c-kit D816V (0.0001|
|
|
| DC48360 | GNF2133 Featured | GNF2133 is a selective DYRK1A inhibitor with an IC50 value of 6 nM. |
|
| DC48361 | Dosimertinib | Dosimertinib is a highly potent, selective, and orally efficacious deuterated EGFR targeting clinical candidate for the treatment of non-small-cell lung cancer. |
|
| DC48362 | OI338 | OI338 is an orally available, ultralong-acting insulin analogue. |
|
| DC48363 | DMPQ dihydrochloride Featured | DMPQ dihydrochloride is a potent and selective inhibitor of human platelet-derived growth factor receptor β (PDGFRβ) with an IC50 of 80 nM. |
|
| DC48364 | Sovleplenib | Sovleplenib is a potent spleen tyrosine kinase (Syk) inhibitor, extracted from patent WO2012167733 A1. |
|
| DC48379 | Zilurgisertib | Zilurgisertib is a selective ALK 2 inhibitor for treating diseases such as cancer. |
|
| DC48380 | Iruplinalkib | Iruplinalkib (WX-0593) is a potent, selective, and orally active inhibitor of ALK and ROS1 tyrosine kinase. Iruplinalkib (WX-0593) shows favorable safety and promising antitumor activity in advanced NSCLC with ALK or ROS1 rearrangement. |
|
| DC48424 | Enbezotinib Featured | Enbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer. |
|
| DC48433 | 4SC-203 (SC71710) | 4SC-203 (SC71710) is a multikinase inhibitor with potential antineoplastic activity. 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs). |
|
| DC48623 | FLT3-IN-10 | FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 has the potential for the treatment of FLT3-mutated acute myeloid leukemia (AML). |
|
| DC48733 | VEGFR-IN-1 | VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively. |
|
| DC48742 | YH-306 Featured | YH-306 is a candidate drug in preventing growth and metastasis of colorectal cancer by modulating FAK signalling pathway. |
|
| DC48857 | HP1142 | HP1142 is a potent and selective inhibitor of FLT3 receptor tyrosine kinase (FLT3/ITD mutation). HP1142 is a benzoimidazole scaffold-based compound. HP1142 has the potential for the research of FLT3/ITD leukemia. |
|
| DC48860 | MAX-40279 Featured | MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032). |
|
| DC48861 | MAX-40279 hydrochloride | MAX-40279 hydrochloride is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hydrochloride has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032). |
|
| DC48896 | FGFR2-IN-2 | FGFR2-IN-2 is a selective FGFR2 inhibitor with an IC50 of 29 nM. |
|
| DC48899 | HP1328 | HP1328 is a potent inhibitor of FLT3 receptor tyrosine kinase (FLT3/ITD mutation). HP1328 is a benzoimidazole scaffold-based compound. HP1328 significantly reduces the leukemia burden and prolongs the survival of mice with FLT3/ITD leukemia. |
|
| DC48943 | YF-452 | YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic drug candidate for cancer research. |
|
| DC48946 | SYK/JAK-IN-1 | SYK/JAK-IN-1 is dual SYK/JAK inhibitor with IC50s of <5 nM for SYK and JAK2, respectively. |
|
| DC48999 | MAX-40279 hemifumarate Featured | MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032). |
|
| DC49000 | Fenlean | Fenlean, a natural squamosamide derivative, is a Src tyrosine kinase inhibitor. Fenlean can inhibit over-activated microglia and protect dopaminergic neurons. Fenlean can attenuate neuroinflammation in Parkinson's disease models. |
|
| DC49068 | AMP-945 | AMP-945 is an inhibitor of the enzyme focal adhesion kinase (FAK). |
|
